Medtronic VenaSeal study shows 88.1% ulcer healing
Medtronic (NYSE: MDT) announced an 88.1% ulcer healing rate in a two-year study of its VenaSeal device for venous leg ulcers. The single-arm study of 125 patients also reported a 96% U.S. insurance coverage rate for the device. The results provide fresh clinical evidence for VenaSeal, with the market's reaction expected on the next trading day.
Becton, Dickinson and Company (BDX) Stock forecasts
Argus has updated its outlook for Becton, Dickinson and Company (BDX), lifting its target price and raising EPS estimates for the medical equipment manufacturer. The report, authored by Senior Analyst David H. Toung, notes BD's operations across four segments: Medical Essentials, Connected Care, BioPharma Systems, and Interventional. The current stock price for BDX is $176.80.
Boston Scientific (BSX) Receives a Buy from RBC Capital
RBC Capital analyst Kendall Au maintained a Buy rating on Boston Scientific (BSX) with a $70.00 price target. This aligns with a general "Strong Buy" consensus among analysts, predicting a 35.51% upside. The company recently reported strong quarterly revenues of $5.44 billion and a net profit of $907 million, alongside positive insider sentiment with increased insider stock purchases.
RBC Capital Reaffirms Their Buy Rating on Zimmer Biomet Holdings (ZBH)
RBC Capital analyst Kendall Au reiterated a Buy rating on Zimmer Biomet Holdings (ZBH) with a price target of $110.00. This affirmation follows the company's Q2 earnings report, which showed increased revenue and net profit compared to the previous year. Zimmer Biomet Holdings currently holds a Moderate Buy consensus among analysts, with an average price target of $106.07.
Medtronic's 49-Year Dividend Streak Faces a New Challenge: Is Growth Finally the Real Story?
Medtronic (MDT), known for its 49-year dividend streak, is experiencing a shift in its investment thesis due to remarkable growth in its cardiac ablation solutions, which grew 88% worldwide. While the dividend provides a floor for the stock, its rapid growth in medical device sectors like ablation is becoming the primary driver for investor interest. Despite its stock performance over the past five years, Medtronic is currently undervalued based on forward earnings, suggesting potential upside if this growth continues.
Boston Scientific Corporation (BSX) Stock forecasts
This article provides an analyst report on Boston Scientific Corporation (BSX) by Morningstar. The report, dated October 2, 2026, highlights competitive pressures affecting key growth areas for the company, which specializes in less invasive medical devices. Debbie S. Wang, a Senior Equity Analyst, authored the report.
Boston Scientific stock hits 52-week low at 42.14 USD
Boston Scientific's stock has fallen to a 52-week low of $42.18, representing a 55% decline over the past year. Despite this downturn, InvestingPro data suggests the stock may be undervalued based on its P/E and PEG ratios. The company has recently faced a cyberattack impacting its operations and financial outlook, leading to reduced price targets from analysts like Wells Fargo, though others like TD Cowen maintain a Buy rating as Boston Scientific works to restore its distribution network.
Bernstein Adjusts Boston Scientific Price Target to $54 From $60, Maintains Outperform Rating
Bernstein has lowered its price target for Boston Scientific (BSX) to $54 from $60 but has kept an Outperform rating on the stock. This adjustment comes amidst other analyst revisions and recent company news, including product recalls and executive changes. The article also provides an overview of Boston Scientific's business segments and financial performance.
Becton, Dickinson and Company (BDX) Stock Forecasts
Argus has updated its outlook on Becton, Dickinson and Company (BDX), lifting its target price and raising EPS estimates for the medical equipment manufacturer. Headquartered in Franklin Lakes, NJ, BD operates through four segments: Medical Essentials, Connected Care, BioPharma Systems, and Interventional. The report, dated October 1, 2026, was authored by David H. Toung, a Senior Analyst specializing in Medical Devices & Healthcare Services.
Elutia receives $8 million escrow from Boston Scientific sale
Elutia Inc. announced it received the full $8 million held in escrow from the sale of its BioEnvelope business to Boston Scientific Corporation. This payment follows a one-year indemnity holdback period and marks a significant financial milestone, ensuring the company has sufficient funding through the first full year of its NXT-41x commercial launch and into 2029 without needing an equity offering. The company is on track for FDA clearance of its NXT-41x antibiotic-eluting surgical matrix in the first half of 2027.
Elutia Reports $8 Million Payment from Boston Scientific
Elutia Inc. has reported receiving an $8 million payment from Boston Scientific. The article, published on MarketScreener, notes Elutia's recent activities including the acquisition of its SimpliDerm business by Cellution Biologics for $11 million and securing a $15 million loan to fund the launch of its NXT-41X product. Elutia is a commercial-stage company focused on developing proprietary drug-eluting biomatrix products for surgical reconstruction.
Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
Elutia Inc. announced it has received an $8 million payment from Boston Scientific, stemming from the sale of its BioEnvelope business. This payment, along with previous financial milestones, means Elutia is now fully funded through the first year of its NXT-41x commercial launch and into 2029, without needing an equity offering. The company is focused on the anticipated FDA clearance of NXT-41x in early 2027, targeting the plastic and reconstructive surgery market.
Context Therapeutics Inc (CNTX-Q) Stock Price and News
This page provides stock price and news updates for Context Therapeutics Inc (CNTX-Q), a women's oncology company focused on developing treatments for hormone-driven cancers. It includes real-time stock data, a summary of recent news articles from sources like Tipranks and GlobeNewswire, and company profile information. Recent news highlights include analyst ratings, clinical trial updates, Nasdaq listing notices, and licensing agreements.
Medtronic drug-coated balloon gets FDA breakthrough status
Medtronic has received FDA breakthrough device designation for its drug-coated balloon catheter designed to treat peripheral artery disease (PAD) below the knee. This is a significant development as current drug-coated balloons are not indicated for use in this area, which is historically difficult to treat and can lead to amputation. Medtronic plans a randomized pivotal trial with approximately 400 patients to study the effectiveness of its IN.PACT BTK paclitaxel-coated device.
Medtronic reveals cardiac mapping and ablation software clearances
Medtronic announced it has received regulatory clearances for new cardiac mapping and ablation software in both the U.S. and Europe. The clearances are for its Affera Prism-2 Mapping Software and a CE mark for the PulseSelect ProxBox Adapter with Proximity Indicator software, aiming to enhance the company's position in the competitive pulsed field ablation market. These software advancements are designed to provide physicians with better visualization and real-time feedback during cardiac ablation procedures.
Boston Scientific misses 2026 guidance as Boston Scientific stock faces a reset
Boston Scientific's 2026 sales and adjusted earnings guidance are under pressure after a cyberattack disrupted manufacturing and order processing. The company expects to provide an updated financial outlook on October 28, 2026, as it works to recover operations. Analysts have lowered price targets for BSX stock, highlighting both the temporary impact of the cyber event and broader product-specific competitive pressures.
Boston Scientific stock after-hours: company warns cyber incident may affect 2026 results
Boston Scientific announced that a cybersecurity incident identified on August 25 is expected to materially affect its third-quarter and full-year 2026 financial results. The incident disrupted manufacturing, order processing, and product shipments, leading the company to anticipate not meeting its previously issued net sales growth and adjusted EPS guidance. Boston Scientific plans to provide an updated operational and financial outlook on October 28, 2026, during its third-quarter conference call.
Boston Scientific stock ahead of the Xetra open as newsroom lists cybersecurity update
Boston Scientific's stock is under scrutiny before the Xetra open due to recent newsroom updates. The company's newsroom has listed a September 22, 2026 update regarding a cybersecurity incident and a July 29 press release detailing its second-quarter 2026 financial results. Boston Scientific Corporation, ticker BSX, is the issuer of these updates.
NeurAxis Positions for Next Phase of Commercial Growth with
NeurAxis, Inc. has appointed Craig Blanchard as Chief Commercial Officer to lead its commercial functions, including sales and marketing. This strategic move aims to strengthen leadership and sales infrastructure as the company anticipates significant expansion and increased insurance coverage for its neuromodulation therapies. Blanchard's experience in commercialization and market development, particularly with medical technologies, is expected to drive broader adoption of IB-Stim and enhance patient access.
A successor's appointment could set the CEO's retirement date at AngioDynamics (ANGO). There's another trigger.
AngioDynamics CEO James C. Clemmer announced his intention to retire by November 30, 2026, or upon the appointment of a successor, with the possibility of monthly extensions by mutual agreement. The company recently amended its fiscal 2026 annual report to include updated XBRL tagging and disclosed performance against cash-incentive targets, showing net sales of $320.2 million against a $312 million target and adjusted EBITDA of $18.2 million versus a $10.5 million target. Executive compensation for fiscal 2026 was largely performance-based, with cash incentive payouts at 180% of target for named executive officers.
Tariff Cuts Put NovoCure Stock And Medical Exporters Back In Focus
Recent tariff cuts between the US and China are re-opening trade channels, specifically benefiting agricultural and medical exporters. This article highlights three US-listed stocks—SWS Hemodialysis Care (SHSE:688410), APT Medical (SHSE:688617), and NovoCure (NVCR)—that are poised to benefit from these policy changes. It encourages investors to examine these and other related companies to assess their altered risk and reward profiles.
NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer
NeurAxis, Inc. has announced the appointment of Craig Blanchard as Chief Commercial Officer, a strategic move to support its anticipated commercial growth. Blanchard will oversee sales and marketing, leveraging his experience to expand the adoption of IB-Stim as the company increases its commercial organization and covered lives. This appointment is crucial for NeurAxis as it aims to capitalize on expanding reimbursement coverage and improve patient access to its FDA-cleared neuromodulation therapy.
GE HealthCare Technologies Inc. (GEHC) Latest Stock News & Headlines
This article provides a compilation of recent news and headlines concerning GE HealthCare Technologies Inc. (GEHC). It covers various topics including dividend announcements, stock performance analysis, market trends in remote cardiac monitoring, and the appointment of new board members. The collected headlines also discuss GEHC's strategic moves like the launch of its CareIntellect AI tool and potential acquisitions.
Kevin Hern from Oklahoma’s 1st congressional district makes multiple trades in Apple and Boston Scientific
Representative Kevin Hern of Oklahoma's 1st congressional district has engaged in multiple stock market transactions involving Apple Inc. and Boston Scientific Corporation. He sold portions of his holdings in both companies from various trust accounts, with Apple sales occurring as the stock neared its 52-week high and was identified as overvalued by InvestingPro analysis. All trades were conducted in compliance with the STOCK Act.
FDA Flags Boston Scientific Catheter Recall
The FDA announced a recall of all Boston Scientific Imager II Angiographic Catheters due to a manufacturing defect. The catheters were produced with inadequate stabilizing agents, increasing the risk of the catheter tip degrading and detaching during medical procedures. While no surge in complaints occurred, Boston Scientific is discontinuing the product line, citing two serious injuries linked to the issue.
CapsoVision Announces FDA Clearance of AI Highlights for CapsoCam Plus
CapsoVision has announced that the FDA has granted 510(k) clearance for AI Highlights, an AI-powered module for its CapsoCam Plus small bowel capsule endoscopy system. This new feature aims to enhance the efficiency and accuracy of reviewing small bowel capsule endoscopy studies by automatically identifying and flagging regions of interest. The company expects the AI Highlights module to be available in the United States in early 2027.
CAIRDAC Appoints Former Axonics CEO Raymond Cohen As Chairman To Advance Self-Powered Pacemaker Technology
CAIRDAC, a French medical technology company, has appointed Raymond W. Cohen, former CEO of Axonics, as Chairman of its Board of Directors. Cohen brings over 40 years of experience in the medical technology industry and will help CAIRDAC advance its Autonomous Leadless Pacing System (ALPS), a self-powered cardiac pacemaker, towards clinical development. The ALPS technology generates electricity from the heart's mechanical movement, aiming to reduce reliance on conventional battery-limited pacemakers.
FDA Finally Approves Watchman Device from Boston Scientific
The FDA has approved Boston Scientific's Watchman Left Atrial Appendage Closure Device, offering a new stroke risk reduction option for high-risk patients with non-valvular atrial fibrillation who cannot take warfarin. This approval is a significant victory for Boston Scientific after more than six years and two previous rejections due to safety and efficacy concerns. The device aims to provide an alternative to long-term warfarin therapy, which many patients cannot tolerate, by preventing blood clots from the left atrial appendage.
ResMed (RMD) Stock Forecast and Price Target 2026 $RMD
ResMed (RMD) has a consensus "Hold" rating from 16 Wall Street analysts, with an average price target of $241.69, suggesting an 8.68% upside from its current price of $222.38. Recent analyst actions include both upgrades and downgrades, with positive sentiment due to strong financial performance and dividend increases, but negative sentiment from insider selling, stock volatility, and increased short interest. The company faces competitive pressures and margin challenges despite its strong position in the sleep apnea treatment sector.
Stryker stock trades at USD 270.92, down 0.91 percent in New York trading
Stryker stock closed at USD 270.92, down 0.91 percent, on September 25, 2026, lagging the DAX. TD Cowen cut its target to USD 298 from USD 355 due to margin concerns, maintaining a Hold rating. The company's next shareholder event is the ex-dividend date on September 30, 2026, for a USD 0.88 distribution.
Expert Voices: HCA Healthcare physician shares how pulsed field ablation is transforming atrial fibrillation care
Dr. John Day, an HCA Healthcare cardiac electrophysiologist, highlights pulsed field ablation as a groundbreaking treatment for atrial fibrillation (AFib), making procedures faster, safer, and more effective. HCA Healthcare physicians are actively involved in research to refine this technology and improve patient outcomes. The article emphasizes the importance of recognizing AFib symptoms and seeking early evaluation due to its links to stroke, heart failure, and dementia.
After cancer treatment, monitoring may reach patients without tumor tissue
Biodesix (BDSX) has announced advancements in two blood-based molecular residual disease (MRD) monitoring programs, collaborating with Bio-Rad Laboratories and Thermo Fisher Scientific. These programs aim to detect circulating tumor DNA (ctDNA) to determine if cancer remains or recurs after treatment. One approach is tumor-informed, utilizing available tumor tissue, while the newly launched tumor-naïve program uses methylation patterns, enabling monitoring for patients whose tumor tissue is unavailable or insufficient.
Boston Scientific stock gains 2.06 percent ahead of the open
Boston Scientific stock (BSX) gained 2.06% ahead of the open, closing at USD 44.62 on September 24, 2026. This gain surpassed the Nasdaq Composite's less than 0.1% advance. The company's stock previously closed at USD 43.72, and upcoming economic data and Federal Reserve remarks are expected to influence broader US equity valuations.
Boston Scientific stock faces a weaker 2026 growth outlook
Boston Scientific (BSX) is facing a weaker growth outlook for 2026, with significant catalysts not expected until 2028, despite strong second-quarter 2026 results that surpassed consensus estimates. The company reported a 7.5% increase in Q2 revenue to $5.44 billion and adjusted EPS of $0.86, up 14.7% year-over-year. Investors are now focused on whether new products can offset pressures in established franchises, given the revised slower growth trajectory.
Boston Scientific stock slips before the bell after September 23 decline
Boston Scientific stock experienced a decline on September 23, 2026, closing down 0.44 percent at USD 43.15, while the broader S&P 500 also fell. The company also announced the retirement of Executive Vice President Arthur C. Butcher, effective January 1, 2027. Investors are now looking towards the next quarterly results scheduled for October 28, 2026.
Wells Fargo Adjusts Price Target on Boston Scientific to $48 From $50, Keeps Equalweight Rating
Wells Fargo has adjusted its price target for Boston Scientific (BSX) from $50 to $48, while maintaining an Equalweight rating on the stock. This update reflects the analyst's current outlook on the medical equipment and materials company. The article also notes other recent analyst rating changes and company news for Boston Scientific.
Intuitive Surgical vs. Stryker: Which MedTech Stock Is the Better Buy Now?
This article compares Intuitive Surgical (ISRG) and Stryker (SYK), two major players in the MedTech sector, evaluating which is the better investment. While Stryker offers diversified MedTech exposure and recovering capital-product momentum, Intuitive Surgical presents a more focused growth story with stronger operational momentum and a growing digital ecosystem. The article concludes that Intuitive Surgical is currently the more attractive bet due to its robotics leadership, recurring revenues, and expanding clinical applications, despite trading at a higher premium.
Boston Scientific (BSX) Executive VP Arthur C. Butcher to Retire in January 2027
Arthur C. Butcher, Executive Vice President and Group President of MedSurg and Asia Pacific at Boston Scientific (BSX), will retire from his current role on January 1, 2027. He will transition to a senior advisor position until February 26, 2027, receiving his current base salary during this period. The company anticipates entering into a retirement agreement with Butcher, providing benefits consistent with its executive retirement plan and incentive programs.
Boston Scientific Corporation Announces Retirement of Arthur C. Butcher from Executive Vice President and Group President, Medsurg and Asia Pacific, Effective January 1, 2027
Boston Scientific Corporation announced that Arthur C. Butcher, Executive Vice President and Group President, MedSurg and Asia Pacific, will retire effective January 1, 2027. Mr. Butcher will continue to serve as a senior advisor until February 26, 2027. This news was disclosed by the company on September 21, 2026.
Boston Scientific Corporation (BSX) Stock Price Today: $44.23
Boston Scientific (BSX) stock is trading at $44.92, showing a 2.74% increase today despite a bearish technical signal. The company reported revenue growth to $20.07 billion in 2025 and a net income margin of 17.5%, but faces near-term challenges from a cyberattack impacting its 2026 guidance. Analysts maintain a consensus price target of $65.20, suggesting potential value with a P/E of 18.06, though investors should consider current operational disruptions and recovery timing.
Medtronic plc (MDT) Options Chain - Yahoo Finance
This article provides the options chain data for Medtronic plc (MDT) from Yahoo Finance. It indicates that as of the reporting time, there are no calls or puts listed for MDT. The article also notes MDT's current stock price, recent dividend announcement, and links to related tickers.
McKesson Narrows Confirmed Data Theft from Its Cyberattack to Oncology and Multispecialty Customers, Promises Patient Notices
McKesson has confirmed that data theft from its August cyberattack is limited to certain third-party applications serving its Oncology & Multispecialty business, affecting patients at cancer centers and specialty practices. The company will notify affected individuals, but has found no indication that its drug distribution business or CoverMyMeds were impacted. While specific details on the number of affected individuals and practices are still emerging, the company advises caution with unexpected communications and suggests monitoring insurance statements.
Form 8K Boston Scientific Corp For: 23 September By Investing.com
This article reports that Boston Scientific Corp filed a Form 8K on September 23, 2026. The Form 8K filing is a key disclosure for public companies, often indicating significant events or changes. The article itself is brief, primarily serving as an announcement of the filing rather than an analysis of its contents.
Boston Scientific announces retirement of executive vice president Arthur C. Butcher
Boston Scientific has announced the retirement of Arthur C. Butcher, Executive Vice President and Group President of MedSurg and Asia Pacific, effective January 1, 2027. Mr. Butcher will transition to a senior advisor role until late February 2027, receiving a prorated base salary and benefits in line with the company's executive retirement plans and equity awards. This announcement follows a recent cybersecurity incident that impacted Boston Scientific's operations, though the company has made significant progress in recovery.
Arthur C. Butcher to Retire as Executive VP & Group President at Boston Scientific
Boston Scientific announced that Arthur C. Butcher will retire as Executive Vice President and Group President, MedSurg and Asia Pacific, effective January 1, 2027. He will continue to serve as a senior advisor through February 26, 2027, receiving a prorated base salary. This information was based on an SEC filing from BOSTON SCIENTIFIC CORP.
Medtronic plc (MDT) latest stock news and headlines
This article provides recent news and financial data for Medtronic plc (MDT), including its latest stock performance, dividend announcement, and various headlines from different financial news sources. It highlights several market forecasts related to medical devices and wearable biosensors, along with news about FDA clearances for Medtronic's Hugo™ RAS system.
Form 8K Boston Scientific Corp For: 23 September By Investing.com
This article reports that Boston Scientific Corp (BSX) filed a Form 8K on September 23, 2026. The filing is a standard report used to announce major events that shareholders should know about. The stock showed a 2.74% increase at the time of publication.
The Premium On Abbott Laboratories Keeps Growing. So Does The Case For Stryker and Boston Scientific
Abbott Laboratories (ABT) trades at a premium valuation compared to its faster-growing rivals, Stryker (SYK) and Boston Scientific (BSX), despite slower operating income growth. Abbott's diversified business and confident forecast support its valuation, while its peers offer more focused growth and higher margins at lower price-to-operating-income ratios. Investors face a decision between Abbott's stability and its competitors' more aggressive growth profiles, with Abbott's second-half performance critical to validating its premium.
Boston Scientific Corp. stock outperforms competitors on strong trading day
Shares of Boston Scientific Corp. (BSX) rose 2.74% on Tuesday, outperforming its competitors and the broader market. This marked the second consecutive day of gains for the stock, despite a mixed trading session for the S&P 500 Index and a decline in the Dow Jones Industrial Average.
Boston Scientific stock advances 2.1 percent ahead of the open
Boston Scientific stock advanced 2.1 percent ahead of the market open, closing at USD 44.66 on the NYSE on September 22, 2026. This gain outperformed the Nasdaq Composite, which rose 0.45 percent on the same day. Despite the positive movement, an analyst noted a slowdown in the United States WATCHMAN market and pressure in the CRM business.
